All News
Filter News
Found 88 articles
-
Elicio Therapeutics Announces Publication of Preclinical Data on ELI-005, a Lymph Node-Targeted Amphiphile Vaccine Against SARS-CoV-2
9/7/2022
Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced the publication of data from a preclinical study evaluating ELI-005, Elicio’s Amphiphile (AMP) adjuvant, AMP-CpG, admixed with the SARS-CoV-2 Spike receptor binding domain (RBD) immunogen, as a lymph node-targeted protein subunit vaccine.
-
Novel Cancer Immunotherapy Clinical Trials Emerging Trends
7/27/2022
Targeted therapies such as immunotherapy harness the potential of immune system to selectively target the cancer cells.
-
Elicio Therapeutics Presents Preclinical Data on AMP-CpG Adjuvant in Combination with EBV Vaccine at the 2022 Keystone Symposia: Viral Immunity: Basic Mechanisms and Therapeutic Applications
7/6/2022
Elicio Therapeutics announced that it presented preclinical data demonstrating its Amphiphile platform adjuvant AMP-CpG combined with cell surface-associated viral protein EBV gp350 and EBVpoly protein, which elicits a robust and durable immune response to Epstein-Barr virus.
-
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Paradigm of Antibody Therapeutics in Lung Cancer Treatment Market
5/27/2022
The newest class of therapeutics of lung cancer is immunotherapy which aims to reawaken or reboot the immune systems to target the cancer cell.
-
Elicio Therapeutics Presents Design of Ongoing AMPLIFY-201 Study in Mutant KRAS-Driven Cancers at ASCO Annual Meeting 2022
5/27/2022
Elicio Therapeutics today announced it is presenting a poster on the AMPLIFY-201 study design at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, being held in-person from June 3-7, 2022, in Chicago.
-
Elicio Therapeutics published data on the preprint server bioRxiv, describing preclinical research into its cancer vaccine that shows a lot of promise.
-
Elicio Therapeutics Announces Publication of Preclinical Data Showing AMP-Peptide Vaccine in Combination with TCR-T Cell Therapy Enhances Anti-Tumor Function and Eradicates Solid Tumors
5/23/2022
Elicio Therapeutics today announced the publication of findings from a preclinical study showing enhanced anti-tumor function and eradication of solid tumors by combining its Amphiphile (AMP) platform vaccine, carrying cognate peptide and adjuvant cargos, with T cell receptor T cell therapies (TCR-Ts).
-
Elicio Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate ELI-002 in Combination with Libtayo® (cemiplimab) in KRAS-Driven Tumors
5/16/2022
Elicio Therapeutics, announced today that it has entered into a clinical supply agreement with Regeneron to evaluate the safety and efficacy of Elicio’s lead asset, ELI-002, an investigational KRAS-targeted cancer vaccine, in combination with Regeneron’s Libtayo® (cemiplimab), a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells, in patients with KRAS-driven tumors.
-
Life sciences and biopharma companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Elicio Therapeutics Announces Appointment of Joy Seymour as Vice President, Head of Regulatory Affairs and Promotion of Dr. Peter DeMuth to Chief Scientific Officer
5/12/2022
Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced the appointment of Joy Seymour as Vice President, Head of Regulatory Affairs and the promotion of Dr. Peter DeMuth to Chief Scientific Officer.
-
Elicio Therapeutics Presents Preclinical Data on the AMP-Peptide Vaccine in Combination with TCR-T Cell Therapy for Solid Tumors at the 2022 Keystone Symposia: Emerging Cellular Therapies
4/29/2022
Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced that it is presenting preclinical data demonstrating robust and durable anti-tumor responses by combining its Amphiphile (AMP) platform vaccine, carrying cognate peptide and adjuvant cargos, with T cell receptor T cell therapies (TCR-Ts).
-
KRAS Inhibitor Market Lumakras Sales KRAS Clinical Development Insight 2028
4/12/2022
The advancement in the field of clinical research has led to identification of several oncogenes which are generally mutated in cancers.
-
Elicio Therapeutics Presents Updated Preclinical Data at Vaccines Summit Boston 2022 on ELI-005, a Lymph Node-Targeted Amphiphile Vaccine, Demonstrating It Induces Potent Cross-Reactive Cellular and Humoral Immunity to SARS-CoV-2
3/29/2022
Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced positive preclinical data demonstrating that ELI-005, a protein subunit vaccine containing the spike receptor-binding domain (RBD) protein of SARS-CoV-2, and Elicio’s lymph node-targeted CpG TLR-9 agonist, Amphiphile-CpG (AMP-CpG), induce potent cross-reactive antibody and T cell responses in mice and non-human primates.
-
Elicio Therapeutics Presents Preclinical Data on its Amphiphile-CpG Adjuvant at the STING & TLR-Targeting Therapies Summit 2022 Digital Event
3/23/2022
Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced the presentation of preclinical data demonstrating that its lymph node-targeted CpG TLR9 agonist, Amphiphile-CpG (AMP-CpG), induces potent immune and anti-tumor responses, at the STING & TLR-Targeting Therapies Summit 2022 Digital Event.
-
CEO to CEO: Tips for First-time Founders
1/11/2022
BioSpace picked the brains of 10 biotech CEOs and founders, to solicit their advice for first-time founders. -
Elicio Therapeutics Presents Preclinical Data on AMP TCR-T and CAR-T Combination Therapies at the 2021 Society for Immunotherapy of Cancer Annual Meeting
11/12/2021
Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced two ePoster presentations of preclinical data on its Amphiphile (AMP) platform in combination with TCR-T and CAR-T therapies, respectively, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting taking place in Washington D.C. and virtually November 10-14, 2021.
-
Flare Therapeutics Appoints Daphne Karydas as COO and CFO, and Michaela Bowden, PhD, as SVP of Biology and Translation
10/25/2021
Flare Therapeutics today announced the appointment of Daphne Karydas as Chief Operating Officer and Chief Financial Officer, and Michaela Bowden, PhD, as Senior Vice President of Biology and Translation.
-
Elicio Therapeutics Announces First Patient Dosed in the ELI-002 (AMPLIFY-201) study in KRAS-Driven Cancers
10/6/2021
Elicio Therapeutics, today announced that the first patient has been dosed with ELI-002, an investigational lymph node-targeted therapeutic vaccine, by Shubham Pant, M.D. at MD Anderson as part of a Phase 1/2 (AMPLIFY-201) study evaluating its safety and efficacy as a treatment for patients with KRAS-driven tumors who have minimal residual tumor cells following surgery to remove the tumor.